Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development

Lead Product(s): Propranolol

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Atnahs Pharma

Deal Size: $390 million Upfront Cash: $350 million

Deal Type: Divestment January 27, 2020

Details:

AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.

Lead Product(s): Evolocumab

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Amgen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 23, 2020

Details:

Under the acquisition, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown.

Lead Product(s): Phenylephrine

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Xellia Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 21, 2020

Details:

Agreement significantly expands biorphen commercial footprint and provides access to institutions that prefer ready-to-use injectable formulations.

Lead Product(s): Cannabidiol

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Health Canada

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 15, 2020

Details:

Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.